Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.
Location: United Kingdom, England, London
Member count: 11-50
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | Syncona Pa... | synconaltd... |